Nifty
:
17853.20
Sensex
:
60048.47
30.25 (0.17%)
163.11 (0.27%)
Nifty
Sensex
:
:
17853.20
60048.47
30.25 (0.17%)
163.11 (0.27%)

Lincoln Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
62/99

BSE: 531633 | NSE: LINCOLN

NSE BSE
383.75
24-Sep-2021
  • Open
  • High
  • Low
  • Previous Close
  •  391.05
  •  395.00
  •  383.00
  •  391.45
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  107011
  •  414.26
  •  407.95
  •  206.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 767.10
  • 11.86
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 753.78
  • 0.39%
  • 1.95

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 37.78%
  • 10.09%
  • 40.52%
  • FII
  • DII
  • Others
  • 0.01%
  • 0.00%
  • 11.60%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.50
  • 3.32
  • 5.03

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 20.51
  • 13.28
  • 5.33

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 28.37
  • 17.21
  • 8.50

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.35
  • 9.49
  • 8.07

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.55
  • 1.66
  • 1.39

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.85
  • 7.03
  • 5.67

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Net Sales
122.19
103.79
17.73%
79.58
78.47
1.41%
114.75
98.52
16.47%
126.06
112.69
11.86%
Expenses
96.88
81.63
18.68%
64.34
69.85
-7.89%
94.74
85.33
11.03%
96.30
88.01
9.42%
EBITDA
25.31
22.17
14.16%
15.24
8.62
76.80%
20.00
13.19
51.63%
29.76
24.68
20.58%
EBIDTM
20.72%
21.36%
19.16%
10.98%
17.43%
13.39%
23.61%
21.90%
Other Income
2.01
1.80
11.67%
2.54
4.19
-39.38%
0.73
3.04
-75.99%
0.60
2.52
-76.19%
Interest
0.38
0.67
-43.28%
0.57
-0.56
-
0.39
1.35
-71.11%
-0.08
0.58
-
Depreciation
1.92
1.88
2.13%
1.89
1.83
3.28%
1.90
1.88
1.06%
1.90
1.77
7.34%
PBT
25.03
21.41
16.91%
15.31
11.53
32.78%
18.44
12.99
41.96%
28.55
24.85
14.89%
Tax
7.33
6.15
19.19%
2.73
2.59
5.41%
4.96
2.07
139.61%
7.63
5.92
28.89%
PAT
17.70
15.26
15.99%
12.58
8.94
40.72%
13.48
10.92
23.44%
20.92
18.93
10.51%
PATM
14.49%
14.70%
15.81%
11.39%
11.75%
11.08%
16.60%
16.80%
EPS
8.85
7.63
15.99%
6.29
4.47
40.72%
6.74
5.46
23.44%
10.46
9.46
10.57%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
442.58
424.19
386.49
366.15
360.61
360.26
400.15
266.07
210.49
194.70
187.58
Net Sales Growth
12.48%
9.75%
5.56%
1.54%
0.10%
-9.97%
50.39%
26.41%
8.11%
3.80%
 
Cost Of Goods Sold
204.09
155.86
138.15
135.66
156.44
202.90
254.64
161.12
123.72
113.96
111.61
Gross Profit
238.49
268.32
248.34
230.49
204.18
157.35
145.50
104.96
86.77
80.74
75.97
GP Margin
53.89%
63.25%
64.26%
62.95%
56.62%
43.68%
36.36%
39.45%
41.22%
41.47%
40.50%
Total Expenditure
352.26
337.01
320.95
298.91
308.30
313.52
359.62
240.47
190.42
179.22
174.08
Power & Fuel Cost
-
7.61
8.18
7.21
6.82
5.92
5.68
4.27
3.40
2.12
0.73
% Of Sales
-
1.79%
2.12%
1.97%
1.89%
1.64%
1.42%
1.60%
1.62%
1.09%
0.39%
Employee Cost
-
60.74
58.65
51.90
51.15
37.59
28.83
17.87
18.57
17.71
16.52
% Of Sales
-
14.32%
15.18%
14.17%
14.18%
10.43%
7.20%
6.72%
8.82%
9.10%
8.81%
Manufacturing Exp.
-
61.08
64.05
60.71
51.73
29.44
35.81
25.98
19.10
17.54
16.91
% Of Sales
-
14.40%
16.57%
16.58%
14.35%
8.17%
8.95%
9.76%
9.07%
9.01%
9.01%
General & Admin Exp.
-
24.35
21.30
20.98
17.50
14.78
20.34
18.86
15.07
13.25
13.36
% Of Sales
-
5.74%
5.51%
5.73%
4.85%
4.10%
5.08%
7.09%
7.16%
6.81%
7.12%
Selling & Distn. Exp.
-
25.72
26.79
20.02
21.24
19.91
10.10
9.42
8.42
13.22
13.66
% Of Sales
-
6.06%
6.93%
5.47%
5.89%
5.53%
2.52%
3.54%
4.00%
6.79%
7.28%
Miscellaneous Exp.
-
1.64
3.83
2.43
3.44
2.97
4.22
2.95
2.13
1.43
13.66
% Of Sales
-
0.39%
0.99%
0.66%
0.95%
0.82%
1.05%
1.11%
1.01%
0.73%
0.68%
EBITDA
90.31
87.18
65.54
67.24
52.31
46.74
40.53
25.60
20.07
15.48
13.50
EBITDA Margin
20.41%
20.55%
16.96%
18.36%
14.51%
12.97%
10.13%
9.62%
9.53%
7.95%
7.20%
Other Income
5.88
5.66
11.04
5.63
5.45
2.78
7.36
7.19
2.49
6.40
3.36
Interest
1.26
1.56
2.02
4.00
5.41
6.66
9.96
8.38
6.97
7.84
7.60
Depreciation
7.61
7.56
7.33
6.68
6.11
5.51
4.87
4.57
3.53
2.65
1.93
PBT
87.33
83.72
67.23
62.19
46.25
37.33
33.07
19.85
12.07
11.38
7.33
Tax
22.65
21.47
15.77
13.46
11.60
9.20
9.27
4.80
1.89
1.85
2.20
Tax Rate
25.94%
25.65%
23.46%
21.64%
25.08%
24.65%
28.03%
24.18%
15.66%
16.26%
30.01%
PAT
64.68
62.22
51.44
48.71
34.62
28.12
23.68
15.01
10.65
9.66
5.12
PAT before Minority Interest
64.65
62.25
51.47
48.74
34.65
28.13
23.80
15.04
10.18
9.53
5.13
Minority Interest
-0.03
-0.03
-0.03
-0.03
-0.03
-0.01
-0.12
-0.03
0.47
0.13
-0.01
PAT Margin
14.61%
14.67%
13.31%
13.30%
9.60%
7.81%
5.92%
5.64%
5.06%
4.96%
2.73%
PAT Growth
19.67%
20.96%
5.60%
40.70%
23.12%
18.75%
57.76%
40.94%
10.25%
88.67%
 
EPS
32.34
31.11
25.72
24.36
17.31
14.06
11.84
7.51
5.33
4.83
2.56

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
375.29
313.09
269.34
224.22
192.38
140.52
111.31
98.81
89.30
80.78
Share Capital
20.00
20.00
20.00
20.00
20.00
16.31
16.31
16.31
16.31
16.31
Total Reserves
355.29
293.09
249.34
204.22
172.38
116.65
95.00
82.50
72.99
64.47
Non-Current Liabilities
26.10
42.85
28.43
24.94
31.75
33.74
33.14
26.18
25.14
22.37
Secured Loans
0.14
0.85
1.69
6.93
12.38
23.62
15.27
16.20
14.41
12.33
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
10.21
3.04
2.66
1.97
Long Term Provisions
15.98
32.51
17.49
7.19
9.98
0.00
0.00
0.00
0.00
0.00
Current Liabilities
92.49
80.32
100.37
113.48
99.42
100.34
114.47
131.05
118.26
104.86
Trade Payables
56.79
51.24
44.01
43.42
32.46
30.38
45.31
66.51
47.51
42.05
Other Current Liabilities
13.43
9.13
11.11
11.11
12.77
15.10
11.52
14.15
15.57
16.25
Short Term Borrowings
0.00
3.83
30.09
48.55
45.04
52.62
50.67
48.46
54.90
46.56
Short Term Provisions
22.26
16.11
15.16
10.41
9.15
2.24
6.97
1.92
0.27
0.00
Total Liabilities
494.29
436.64
398.50
362.97
323.85
274.79
261.85
259.75
236.88
212.31
Net Block
119.86
122.72
120.91
116.58
102.71
98.47
65.62
65.07
64.94
37.74
Gross Block
151.27
146.70
138.11
127.65
108.16
120.89
87.50
82.22
78.82
49.07
Accumulated Depreciation
31.41
23.98
17.21
11.08
5.45
22.42
21.88
17.15
13.89
11.33
Non Current Assets
168.89
173.91
159.43
136.08
134.27
127.83
80.64
110.69
113.67
90.73
Capital Work in Progress
1.69
0.04
2.10
0.29
6.63
2.73
2.55
2.37
2.37
13.51
Non Current Investment
0.09
0.09
0.09
0.09
0.09
0.01
0.01
0.41
0.41
0.41
Long Term Loans & Adv.
46.81
51.02
36.01
18.79
24.48
26.62
12.47
42.84
45.95
39.08
Other Non Current Assets
0.45
0.03
0.33
0.34
0.36
0.00
0.00
0.00
0.00
0.00
Current Assets
325.40
262.73
239.08
226.88
189.58
146.98
181.20
149.06
123.21
121.58
Current Investments
80.66
34.22
18.07
10.97
10.25
0.00
0.00
0.00
0.00
0.00
Inventories
46.61
47.40
36.23
45.41
37.31
27.48
21.82
23.84
19.33
21.41
Sundry Debtors
111.33
101.34
122.47
109.44
90.67
80.53
119.01
89.04
74.79
65.37
Cash & Bank
13.84
14.58
7.58
14.59
11.68
12.66
11.51
10.45
15.15
16.86
Other Current Assets
72.95
1.11
1.10
1.29
39.68
26.31
28.86
25.73
13.94
17.94
Short Term Loans & Adv.
71.52
64.09
53.64
45.18
39.02
26.26
28.86
25.73
13.94
17.94
Net Current Assets
232.91
182.41
138.71
113.40
90.16
46.63
66.73
18.01
4.95
16.72
Total Assets
494.29
436.64
398.51
362.96
323.85
274.81
261.84
259.75
236.88
212.31

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
69.27
75.42
52.84
26.63
25.04
44.80
24.56
4.64
-15.60
11.87
PBT
83.72
67.23
62.19
46.25
37.33
33.07
19.85
12.07
9.53
5.13
Adjustment
4.84
8.66
9.30
11.64
10.70
13.75
10.68
12.75
8.96
14.32
Changes in Working Capital
0.20
14.33
-1.12
-22.00
-13.24
4.80
-2.50
-17.56
-32.36
-6.38
Cash after chg. in Working capital
88.76
90.22
70.38
35.88
34.79
51.62
28.02
7.26
-13.87
13.07
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-19.49
-14.81
-17.53
-9.25
-9.75
-6.82
-3.46
-2.62
-1.73
-1.20
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-64.23
-30.88
-18.19
-11.77
-25.48
-41.79
6.52
1.45
-16.27
-27.23
Net Fixed Assets
-5.71
-5.59
-11.52
-12.45
4.05
-29.04
-4.21
-0.95
-2.89
-4.61
Net Investments
-46.39
-14.20
-7.10
-2.72
-16.01
-7.34
-1.43
0.00
0.00
-11.16
Others
-12.13
-11.09
0.43
3.40
-13.52
-5.41
12.16
2.40
-13.38
-11.46
Cash from Financing Activity
-5.75
-37.76
-35.77
-11.41
0.30
-3.42
-32.04
-10.51
29.30
16.19
Net Cash Inflow / Outflow
-0.70
6.77
-1.11
3.45
-0.14
-0.41
-0.96
-4.42
-2.57
0.82
Opening Cash & Equivalents
12.14
5.46
6.57
3.12
3.26
3.75
4.82
9.39
11.97
11.53
Closing Cash & Equivalent
11.44
12.23
5.46
6.57
3.12
3.43
3.87
4.97
9.39
12.36

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
187.65
156.54
134.67
112.11
96.19
81.52
68.24
60.58
54.75
49.53
ROA
13.37%
12.33%
12.80%
10.09%
9.40%
8.87%
5.77%
4.10%
4.25%
2.72%
ROE
18.09%
17.67%
19.75%
16.63%
17.29%
19.49%
14.32%
10.83%
11.21%
6.51%
ROCE
24.58%
22.30%
22.50%
19.05%
18.51%
21.18%
15.91%
11.48%
12.21%
10.94%
Fixed Asset Turnover
2.94
2.81
2.84
3.07
3.19
3.90
3.20
2.67
3.10
4.45
Receivable days
88.50
102.22
112.23
100.99
85.52
89.69
139.97
139.16
128.96
100.92
Inventory Days
39.12
38.19
39.51
41.74
32.36
22.16
30.72
36.67
37.48
45.44
Payable days
62.27
56.60
57.26
47.62
37.21
40.22
92.31
115.76
98.21
75.46
Cash Conversion Cycle
65.35
83.82
94.48
95.11
80.67
71.63
78.37
60.06
68.23
70.90
Total Debt/Equity
0.00
0.02
0.12
0.27
0.34
0.59
0.69
0.69
0.85
0.86
Interest Cover
54.60
34.32
16.56
9.55
6.60
4.32
3.37
2.73
2.45
1.96

Annual Reports:

FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012

News Update:


  • Lincoln Pharmaceuticals planning to launch Cephalosporin products
    21st Sep 2021, 12:19 PM

    The Company has acquired a facility in Mehsana, Gujarat. Investment in Cephalosporin plant for Rs 30 crore

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.